Payment overview · 2025
General Payments
$151.05
8 reported records · 5 companies
Healthcare provider profile · identity verified
Matthew Timothy Porter, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · ROLLA, MO · NPI 1477791606
Verified facts
What the public records show
CMS Open Payments records show Matthew Timothy Porter, M.D. received $151.05 in general payments during 2025 across 8 reported records.
PFIZER INC. accounted for 47.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 8 associated products.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 201 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 93 claims for Trulicity by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 44 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| PFIZER INC. | Unresolved — no canonical attribution shown | $71.34 | 47.2% | 4 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $23.22 | 15.4% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $21.47 | 14.2% | 1 | 2025 |
| Braeburn Inc. | Unresolved — no canonical attribution shown | $20.74 | 13.7% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $14.28 | 9.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $151.05 | 8 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $38.72 | 2 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $38.72 | 2 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $38.72 | 2 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $32.62 | 2 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $32.62 | 2 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $23.22 | 1 | 2025 |
Source payment records
|
|||||
| BRIXADI Normalized: brixadi |
Drug | Braeburn Inc. | $20.74 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $14.28 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
201 | 35 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
30 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
93 | 21 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
44 | 12 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 414 | 91 |
| Gabapentin | Gabapentin | 258 | 45 |
| Lisinopril | Lisinopril | 239 | 53 |
| Levothyroxine Sodium | Levothyroxine Sodium | 206 | 36 |
| Jardiance | Empagliflozin | 201 | 35 |
| Metformin Hcl | Metformin Hcl | 163 | 30 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 154 | 33 |
| Potassium Chloride | Potassium Chloride | 140 | 27 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 128 | 23 |
| Amlodipine Besylate | Amlodipine Besylate | 123 | 23 |
| Buprenorphine-Naloxone | Buprenorphine Hcl/Naloxone Hcl | 109 | 15 |
| Omeprazole | Omeprazole | 107 | 26 |
| Meloxicam | Meloxicam | 106 | 20 |
| Pregabalin | Pregabalin | 105 | 18 |
| Fluticasone Propionate | Fluticasone Propionate | 103 | 30 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 103 | 25 |
| Furosemide | Furosemide | 96 | 27 |
| Trulicity | Dulaglutide | 93 | 21 |
| Duloxetine Hcl | Duloxetine Hcl | 89 | 16 |
| Alprazolam | Alprazolam | 87 | 13 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 84 | 25 |
| Trazodone Hcl | Trazodone Hcl | 82 | 19 |
| Clopidogrel | Clopidogrel Bisulfate | 80 | 19 |
| Hydrochlorothiazide | Hydrochlorothiazide | 78 | 19 |
| Escitalopram Oxalate | Escitalopram Oxalate | 76 | 19 |
| Pantoprazole Sodium | Pantoprazole Sodium | 70 | 12 |
| Losartan Potassium | Losartan Potassium | 68 | 16 |
| Carvedilol | Carvedilol | 67 | 15 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 65 | 14 |
| Sertraline Hcl | Sertraline Hcl | 65 | 14 |
| Tamsulosin Hcl | Tamsulosin Hcl | 64 | 15 |
| Metformin Hcl Er | Metformin Hcl | 62 | 14 |
| Montelukast Sodium | Montelukast Sodium | 62 | 11 |
| Ozempic | Semaglutide | 58 | 12 |
| Fluoxetine Hcl | Fluoxetine Hcl | 56 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 56 | 12 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 53 | 15 |
| Baclofen | Baclofen | 50 | 12 |
| Citalopram Hbr | Citalopram Hydrobromide | 50 | 11 |
| Quetiapine Fumarate | Quetiapine Fumarate | 49 | suppressed |
| Ibuprofen | Ibuprofen | 48 | 15 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 47 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 46 | 13 |
| Metoprolol Succinate | Metoprolol Succinate | 45 | suppressed |
| Eliquis | Apixaban | 44 | 12 |
| Farxiga | Dapagliflozin Propanediol | 43 | suppressed |
| Januvia | Sitagliptin Phosphate | 38 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 38 | 33 |
| Symbicort | Budesonide/Formoterol Fumarate | 38 | suppressed |
| Fluconazole | Fluconazole | 37 | 26 |
| Tramadol Hcl | Tramadol Hcl | 37 | 12 |
| Famotidine | Famotidine | 36 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 34 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 32 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 32 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 32 | suppressed |
| Naproxen | Naproxen | 31 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 30 | suppressed |
| Mounjaro | Tirzepatide | 30 | suppressed |
| Topiramate | Topiramate | 29 | suppressed |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 28 | 28 |
| Humalog Kwikpen U-100 | Insulin Lispro | 27 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 27 | suppressed |
| Spironolactone | Spironolactone | 26 | suppressed |
| Allopurinol | Allopurinol | 25 | suppressed |
| Nifedipine Er | Nifedipine | 25 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 25 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 25 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 25 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 25 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 24 | suppressed |
| Mirtazapine | Mirtazapine | 24 | suppressed |
| Chlorthalidone | Chlorthalidone | 23 | suppressed |
| Tradjenta | Linagliptin | 23 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 22 | suppressed |
| Glipizide Er | Glipizide | 22 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 22 | suppressed |
| Simvastatin | Simvastatin | 22 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 21 | suppressed |
| Quetiapine Fumarate Er | Quetiapine Fumarate | 21 | suppressed |
| Sucralfate | Sucralfate | 21 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 20 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 20 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 20 | suppressed |
| Xarelto | Rivaroxaban | 20 | suppressed |
| Comfort Ez Pen Needle | Pen Needle, Diabetic | 19 | suppressed |
| Entresto | Sacubitril/Valsartan | 19 | suppressed |
| Invega Sustenna | Paliperidone Palmitate | 19 | suppressed |
| Levetiracetam | Levetiracetam | 19 | suppressed |
| Lurasidone Hcl | Lurasidone Hcl | 19 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 19 | 12 |
| Prednisone | Prednisone | 19 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 19 | suppressed |
| Techlite Pen Needle | Pen Needle, Diabetic | 19 | suppressed |
| Telmisartan | Telmisartan | 19 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 19 | suppressed |
| Atenolol | Atenolol | 18 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 18 | 14 |
| Incruse Ellipta | Umeclidinium Bromide | 18 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 18 | suppressed |
| Aripiprazole | Aripiprazole | 17 | suppressed |
| Bupropion Xl | Bupropion Hcl | 17 | suppressed |
| Clonazepam | Clonazepam | 17 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 17 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 17 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 17 | suppressed |
| Ramipril | Ramipril | 17 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 16 | suppressed |
| Loperamide | Loperamide Hcl | 16 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 16 | suppressed |
| Victoza 2-Pak | Liraglutide | 16 | suppressed |
| Celecoxib | Celecoxib | 15 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 15 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 15 | 11 |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 15 | suppressed |
| Glipizide | Glipizide | 15 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 14 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 14 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 14 | suppressed |
| Valsartan | Valsartan | 14 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 14 | suppressed |
| Atrovent Hfa | Ipratropium Bromide | 13 | suppressed |
| Colchicine | Colchicine | 13 | suppressed |
| Dutasteride | Dutasteride | 13 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 13 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 13 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 13 | suppressed |
| Boostrix Tdap | Diphth,pertuss(Acell),tet Vac | 12 | 12 |
| Donepezil Hcl | Donepezil Hcl | 12 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 12 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 12 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 12 | suppressed |
| Omnipod 5 Dexg7g6 Pods (Gen 5) | Insulin Pump Cart,auto,bt,g6/7 | 12 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 11 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 11 | suppressed |
| Glimepiride | Glimepiride | 11 | suppressed |
| Ketoconazole | Ketoconazole | 11 | suppressed |
| Lansoprazole | Lansoprazole | 11 | suppressed |
| Verapamil Er | Verapamil Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $151.05 · 8 records | PFIZER INC. | ABRYSVO, BRIXADI, CAPLYTA, COMIRNATY, NURTEC ODT, PREVNAR 20, VRAYLAR, ZAVZPRET | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with Lilly USA, LLC?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error